Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Rheumatoid Arthritis
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Masking Description: This is a randomized, open label trialPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Primary objective To examine: Pain characteristics in participants with active rheumatoid arthritis receiving abatacept biologic therapy versus TNF inhibitor therapy in the form of adalimumab. To establish if there are differences in pain outcomes by patient reported scores, objective measures of pa...
Primary objective To examine: Pain characteristics in participants with active rheumatoid arthritis receiving abatacept biologic therapy versus TNF inhibitor therapy in the form of adalimumab. To establish if there are differences in pain outcomes by patient reported scores, objective measures of pain using quantitative sensory testing and inflammatory markers in participants receiving biologic therapies for rheumatoid arthritis. Population: The population being assessed in this study are participants with active rheumatoid arthritis with a disease activity score of greater than 5.1. Intervention: Subjects will be randomized to treatment with abatacept or adalimumab for active rheumatoid arthritis Comparison group: Abatacept is being compared to adalimumab therapy in the trial
Tracking Information
- NCT #
- NCT04255134
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Prof Sofat, MD, PhD St George's, University of London
Get Well Soon